Bioporto A/S (FRA:2P4)

€ 0.2835 0.015 (5.59%) Market Cap: 127.83 Mil Enterprise Value: 122.64 Mil PE Ratio: 0 PB Ratio: 21.36 GF Score: 42/100

Preliminary Q4 2023 Bioporto A/S Investor Presentation (Online) Transcript
Feb 22, 2024
Q3 2023 Bioporto A/S Earnings Call Transcript
Nov 01, 2023

€0.2085 (+8.48%)

Earnings
Q2 2023 Bioporto A/S Earnings Call Transcript
Aug 01, 2023

€0.155 (+3.61%)

Earnings
Bioporto A/S Investor Webcast Transcript
May 31, 2023
Q1 2023 Bioporto A/S Earnings Call Transcript
May 10, 2023

€0.206793 (+6.63%)

Earnings
Q4 2022 Bioporto A/S Earnings Call Transcript
Mar 30, 2023

€0.203457 (+4.66%)

Earnings
Q4 2022 Bioporto A/S Earnings Presentation Transcript
Mar 30, 2023
Q3 2022 Bioporto A/S Earnings Call Transcript
Nov 09, 2022

€0.273024 (-1.38%)

Earnings
Q2 2022 Bioporto A/S Earnings Call Transcript
Aug 17, 2022

€0.187924 (+3.79%)

Earnings
Q1 2022 Bioporto A/S Earnings Call Transcript
May 11, 2022

€0.108066 (-7.05%)

Earnings

Bioporto A/S Investor Webcast Transcript

May 31, 2023 / 10:00AM GMT

Release Date Price: €0.186399 (-0.10%)

Transcript

Unidentified Participant

So now, the time is 12 o'clock. It's noon here in Europe, and this event with BioPorto is represented by their senior management: CEO, Tony Pare; and their CFO, Neil Goldman.

And to the audience, thanks a lot for participating in great numbers with such short notice. And that's, of course, due to the capital increase in BioPorto. They'd sent out a message this morning.

(Instructions) So by that said, I would like to welcome everybody. And please Tony and Neil, carry on.

Tony Pare;S;CEO

BioPorto A

/-

Thank you, Klaus, for hosting us today. I would like to start out with expressing my appreciation to all of our shareholders for their continued support as we progress to get this life-saving test for identifying acute kidney disease to the market globally. As you know, the largest market is in the US, and our continued focus is to get our test FDA cleared.

This presentation contains forward-looking statements. This slide contains important disclosures regarding those forward-looking

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.